Global Atopic Dermatitis Therapeutics
Market Report
2025
Atopic Dermatitis Therapeutics Market Report 2025 (Global Edition)
Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Atopic Dermatitis Therapeutics Market Report 2024.
Global Atopic Dermatitis Therapeutics Market Report 2024 Market Size Split by Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others), by End User (Hospitals, Resear...
According to Cognitive Market Research, The Atopic Dermatitis Market will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031.
The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future.
Europe accounted for a market share of over XX% of the global revenue with a market size of USD XX million.
Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
The Atopic Dermatitis Market held the highest market revenue share in 2024.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Market Size | 121212 |
| Country Market Size | 121212 |
| North Americ Market Size | 121212 |
| Europe Market Size | 121212 |
| Asia Pacific Market Size | 121212 |
| South America Market Size | 121212 |
| Middle East and Africa Market Size | 121212 |
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
| |
| Market Split by Drug Class |
|
| Market Split by End User |
|
| Market Split by Route of Administration |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Report scope is customizable as we have a huge database of Atopic Dermatitis Therapeutics industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Atopic Dermatitis Therapeutics Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Atopic Dermatitis Therapeutics Market Report Description
Introduction of The Atopic Dermatitis Market
The skin disease known as atopic dermatitis produces dry, itchy, and inflammatory skin. Though it can occur at any age, small children are most likely to experience it. Atopic dermatitis is a long-term illness that occasionally flares up. It's not contagious, although it can be bothersome.
Atopic dermis often begins in childhood and might get worse as people get older. Atopic dermatitis is an inflammatory skin condition that is caused by changes in immunologic, genetic, pharmacological, and environmental variables. It can be chronic or recurrent. Asthma and allergic rhinitis are common co-occurring atopic illnesses that initially manifest as atopic dermatitis (40–60% of the cases), as per a phenomenon called the atopic march. It is among the most common skin conditions, with lifetime incidence rates of 1-3% for adults and 15-20% for children worldwide.
The American Journal of Managed Care reports that atopic dermatitis affects up to 15 million people in the country. Ten to twenty percent of newborns will develop atopic dermatitis. But as they become older, nearly half of them outgrow it or get much better. Atopic dermatitis affects people of both sexes equally and is more common in people who have a personal or family history of asthma, environmental allergies, or food allergies. Anywhere on the skin could experience atopic dermatitis symptoms. It commonly affects the hands, inner elbows, neck, foot, knees, ankle, and area surrounding the eyes in both children and adults.
Due to their allergies, which include those that can lead to morbidities like asthma and allergic rhinitis, the patient is highly susceptible. There's a chance the condition will become chronic and that it will sometimes get worse and spread. Acne is treated using atopic dermatitis drugs, such as atopic eczema steroids, which also reduce inflammation and other problems caused by the condition.67% of children who commonly have sleep problems have atopic dermatitis. Children's growth may be hampered by sleep deprivation. They also suffer from food allergies, allergic rhinitis, and asthma. Usually starting in infancy, atopic dermatitis develops into additional allergic disorders as people age. These elements drive the market for atopic dermatitis.
Biologic therapy for atopic dermatitis has had a good response. Overall quality of life has increased as a result of these interventions. As a result, there is a noticeable increase in demand for biologic medications for treating atopic dermatitis, and this trend is probably going to continue in the coming years.
One of the main reasons propelling the growth of the atopic dermatitis treatment market is the rise in the incidence of atopic dermatitis among people worldwide. The market for atopic dermatitis therapies is expanding faster than it would otherwise due to rising public knowledge of the disease's treatment options and an increase in government attempts to offer better, more accessible care. The market for treatments for atopic dermatitis is further influenced by the existence of advantageous reimbursement policies and the growth in popularity of these therapies due to digital ads. Additionally, the market for treatments for atopic dermatitis is favourably impacted by the aging population, advancements in healthcare infrastructure, and rising healthcare costs.
Atopic Dermatitis Therapeutics Market Size
Market Dynamics of the Atopic Dermatitis Market
Key Drivers for The Atopic Dermatitis Market
- Rising prevalence of atopic dermatitis fuels, the growth of the atopic dermatitis market
It is anticipated that the increased incidence of atopic dermatitis will drive the market's expansion. Eczema, another name for atopic dermatitis, is a skin disorder that makes the skin dry and itchy. The demand for atopic dermatitis diagnosis and treatment is growing due to the disease's rising prevalence. Global differences in dermatological problems can be attributed to factors such as climate, age, gender, socioeconomic level, lifestyle, genetics, and personal habits. One of the main factors propelling the growth of the atopic dermatitis medications market is the high incidence of atopic dermatitis worldwide.
For instance, in July 2021, The National Eczema Association, a US-based organization dedicated to raising awareness of eczema, estimates that 31.6 million Americans, or almost 10% of the population, suffered from eczema in 2021. Nine million children under the age of eighteen suffered from atopic dermatitis, with 80% of those cases occurring before the age of six. As a result, the market for atopic dermatitis is expanding because of the rising incidence of the condition.
Source:(https://nationaleczema.org/research/eczema-facts/)
Thus, the rising prevalence of atopic dermatitis is a key driver fueling the growth of the atopic dermatitis market, as increasing cases necessitate greater demand for effective treatments and therapies.
- Market demand for atopic dermatitis is driven by a growing need for personalized medicine
The market for atopic dermatitis is anticipated to increase at a rapid pace in the future due to the growing usage of personalized therapy. Personalized medicine is a cutting-edge approach to healthcare and medical treatment that customizes pharmacological regimens, medical practices, choices, and interventions for each patient. In the case of atopic dermatitis, personalized medicine entails identifying certain genetic and molecular variables impacting the condition, allowing for the creation of tailored medicines that take into account each patient's particular traits. This strategy reduces side effects while simultaneously improving therapeutic effectiveness.
For instance, in October 2022, Reports from the US-based health-focused news organization STAT stated that there were 300 customized medications and over 75,000 genetic testing products available. Thus, the market for atopic dermatitis is expanding due to the growing need for tailored therapy.
Source:(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142561/)
Thus, Market demand for atopic dermatitis is propelled by the growing need for personalized medicine, indicating a shift towards tailored treatments that address individual patient needs and characteristics, driving innovation and market growth.
Restraint Factor for The Atopic Dermatitis Market
- Expiry of patents or loss of patents restrain the growth of the global atopic dermatitis drugs market.
Large corporations that possess their patents are seriously threatened by the loss or revocation of those patents. In the end, generic medications tend to overtake original products on the market as a result of patent losses or expirations, costing big businesses their margins and competitive edge. Medicines that are accessible at a reduced cost but are comparable to branded medications in terms of quality, dose form, strength, and efficacy are known as generics. The low cost of these generic medications means that rising generic drug penetration will restrain market expansion.
The operations of a pharmaceutical company are impacted by claims that third parties are violating patents and other intellectual property rights. The market will see a rise in generic medications as a result of the patent on branded atopic dermatitis medications expiring, which will lower sales of branded medications and perhaps harm the bottom line of well-known suppliers. As a result, during the projection period, this will impair chances for revenue growth in the market under consideration.
Thus, the expiry or loss of patents presents a significant restraint to the growth of the global atopic dermatitis drugs market, as it opens the door to generic competition, reducing market exclusivity and potentially impacting revenue streams for pharmaceutical companies.
How did COVID-19 impact The Atopic Dermatitis Market
The COVID-19 pandemic has harmed the worldwide market for atopic dermatitis. Atopic dermatitis is a skin ailment that affects a significant portion of the global population. COVID-19 has a detrimental effect on the market for atopic dermatitis expansion. First and foremost, the COVID-19 pandemic has severely disrupted the ecology of the supply chain by causing a lack of medications and treatment protocols for atopic dermatitis. Furthermore, a few nations' governments have mandated that people maintain social distance. As a result, the market's growth has been adversely impacted by individuals with atopic dermatitis who have temporarily ceased going to hospitals for illness monitoring and have instead begun exploring alternative treatments.
Furthermore, the COVID-19 pandemic postponed clinical studies intended to provide novel medications and therapeutic approaches to the market for atopic dermatitis. Similarly, the COVID-19 pandemic has had a major detrimental effect on the atopic dermatitis business. Nonetheless, given the COVID-19 pandemic's diminished effects, the atopic dermatitis market is anticipated to grow at a respectable rate throughout the course of the projection period.
For instance, Companies manufacturing biologic therapies such as Dupixent (dupilumab) by Regeneron Pharmaceuticals and Sanofi have had to navigate disruptions in clinical trials, supply chains, and patient access due to the pandemic. Additionally, companies producing topical treatments and emollients may have faced challenges in production and distribution during lockdowns and supply chain disruptions.
Source:(https://www.sanofi.com/en/media-room/press-releases/2023/2023-11-27-06-30-00-2785836)
Overall, COVID-19 has affected various aspects of the atopic dermatitis market, from patient care and treatment access to the operations of pharmaceutical companies producing relevant therapies.
Opportunities for The Atopic Dermatitis Market
- Advancement of products transforms the atopic dermatitis market which drives the market.
The market for atopic dermatitis is seeing a significant increase in the popularity of product advancements. To improve their market position, major players in the industry are launching cutting-edge products.
For instance, in June 2022, The FDA approved Dupixent (dupilumab) for use by US biotechnology company Regeneron Pharmaceuticals Inc. Children aged six months to five years who have moderate-to-severe atopic dermatitis are prescribed dupixent. Dupixent can be taken with or without topical corticosteroids. Dupixent works by blocking the signaling of two main Type 2 inflammatory sources (IL-4 and IL-13), which are important in the development of asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.
Source:(https://www.sanofi.com/en/media-room/press-releases/2022/2022-06-07-20-45-00-2458243#:~:text=June%207%2C%202022.,those%20therapies%20are%20not%20advisable.)
Therefore, Advancements in product offerings are transforming the atopic dermatitis market, driving growth by introducing innovative therapies, formulations, and delivery methods that better address patient needs, improve efficacy, and enhance treatment outcomes.
We have various report editions of Atopic Dermatitis Therapeutics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape: The Atopic Dermatitis Market
The market for atopic dermatitis is quite competitive worldwide. This is linked to an increase in the burden or prevalence of atopic dermatitis worldwide; thus, market participants are concentrating on introducing innovative products. The anticipated launch of novel products throughout the forecast period is expected to fuel competitive rivalry in the market, which is projected to stay high during that period. Players are increasingly working together, and alliances are being established to create and market new goods. The market's strong profitability during the epidemic is drawing new competitors with creative ideas, making it more competitive for already established businesses.
Some of the key players in the global atopic dermatitis market are Pfizer Inc., Novartis AG, Nestle, LEO Pharma AS, Encore Dermatology Inc., GlaxoSmithKline PLC, Allergan PLC, AbbVie Inc., Regeneron Pharmaceuticals Inc., and Bausch Health Companies Inc., among others.
For instance, in September 2022, Ducentis BioTherapeutics was purchased by Arcutis Biotherapeutics, a US-based commercial-stage biopharmaceuticals business, for an unknown sum. Through the acquisition, Arcutis would be able to fulfill its goal of becoming the market leader in medical dermatology and provide drugs to address patients' unmet dermatological requirements. A US-based preclinical-stage biotechnology startup called Ducentis BioTherapeutics is working on lead indications for atopic dermatitis.
Source:(https://www.arcutis.com/arcutis-announces-acquisition-of-ducentis-biotherapeutics-ltd/)
Top Companies Market Share in Atopic Dermatitis Therapeutics Industry: (In no particular order of Rank)
- Abbvie Inc
- Bayer AG
- Allergan PLC
- Novartis AG
- Astellas Pharma Inc.
- GALDERMA LABORATORIES
- L.P.
- F. Hoffmann-La Roche Ltd.
- Bausch Health Companies Inc
- Nestle SA
- Pfizer Inc
- AstraZeneca
- Regenron Pharmaceutical Inc
- Evelo Biosciences
- Cara Therapeutics
- Bristol-Myers Squibb Company
- GlaxoSmithKline PLC
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Regional Analysis of the Atopic Dermatitis Market
Which Region Will Dominate the Market in 2024?
According to Cognitive Research, the North American region dominated the market and accounted for the highest revenue of XX% in 2024 and it is projected that it will grow at a CAGR of XX% in the future. As of 2023, the North American market held a substantial portion of the worldwide market, and it is expected to continue to dominate over the projected period. It can be attributed to lifestyle modifications, early treatment uptake, and the introduction of new products. Recent research shows that 16.8 million Americans suffer from moderate to severe atopic dermatitis, which causes pain, physical discomfort, mental load, and sleep disruption in 40% of the population. This skin condition mostly affects the area around the neck, face, and eyes and causes rashes and itchy skin patches. Furthermore, atopic dermatitis affects 18% of Canadians Atopic Dermatitis. It is an apparent skin condition that lowers quality of life by causing psychological stress, anxiety, and depression. Abrocitinib, or CIBINQO, has been licensed by Health Canada for the treatment of atopic dermatitis in individuals 12 years of age and older. Nonetheless, a large number of Atopic Dermatitis patients in Canada require mental health services and wish to engage with peers for further support.
Which Region Is Expanding at The Fastest CAGR?
Asia Pacific is expected to be the fastest expanding region with a CAGR of XX% from 2024 to 2031 in the forecast period. India is expected to have the greatest CAGR throughout that time. The substantial unmet clinical demands of the victims, rising healthcare costs, and the availability of appropriate treatment are all responsible for this region-wide expansion. Atopic dermatitis guidelines have been issued by members of the Indian Dermatology Expert Board. Modern medications and therapies are offered for Parkinson's disease in India. As Atopic Dermatitis cases increase, more hospitals are implementing treatment programs for this illness. The primary cause of this was India's changing climate. Over the previous ten years, China has seen a sharp rise in the incidence of Atopic Dermatitis. Over the previous ten years, China has seen a sharp rise in the incidence of Atopic Dermatitis. Most individuals with these disorders, who need treatment, are between the ages of 10 and 30. Guidelines for the Diagnosis and Treatment of Atopic Dermatitis in China were created by the Chinese Society of Dermatology Immunology Group. The market will develop due to the quick progress made in China and around the world in the last five years in the diagnosis and treatment of Atopic dermatitis. In Japan, Atopic dermatitis is the second most prevalent skin condition. Most youngsters in Japan are afflicted with this illness. The oral medication CIBINQO was authorized by the Japanese Ministry of Health, Labor, and Welfare (MHLW) in 2021 for the treatment of individuals with moderate to severe atopic dermatitis. In addition, Otsuka Pharmaceutical Co., Ltd.'s Moizerto Ointment was authorized in Japan in 2021 for the treatment of atopic dermatitis.
The current report Scope analyzes Atopic Dermatitis Therapeutics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Atopic Dermatitis Therapeutics Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Atopic Dermatitis Therapeutics Market Analysis
Global Atopic Dermatitis Therapeutics Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Atopic Dermatitis Therapeutics Industry growth. Atopic Dermatitis Therapeutics market has been segmented with the help of its Drug Class , End User Route of Administration, and others. Atopic Dermatitis Therapeutics market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Segment Performance in The Atopic Dermatitis Market
Drug Class Segment Analysis
Based on drug class, the market is segmented into Corticosteroids, Emollients/Moisturizers, IL-4 and PDE4 Inhibitors, Calcineurin Inhibitors, Antibiotics, and Other Drug Classes. In 2023, the biologics category accounted for the highest proportion, surpassing 40%. Since biologics target the inflammatory mechanisms fueling the illness rather than merely treating its symptoms, they have a significant therapeutic benefit over traditional topical therapies. These medications have a competitive advantage because of their great specificity. When a patient is resistant to previous systemic therapy, biologics are often administered as second or third-line treatment for severe situations. The increasing need for biologics owing to their high effectiveness, the increase in product approvals, and the availability of a strong pipeline of biologic medications for atopic dermatitis all contribute to the biologics segment's growth. Nemolizumab, a monoclonal antibody that GALDERMA LABORATORIES, L.P. is now developing, is being studied for the potential treatment of atopic dermatitis and pruritus.
Due to increased product availability, the PDE4 category is anticipated to rise considerably throughout the projection period. One authorized PDE4 inhibitor is Eucrisa (crisaborole ointment, 2%). In 2016, the FDA gave Pfizer's Eucrisa approval to treat mild-to-moderate Atopic Dermatitis. It has been demonstrated to suppress cytokines generated from Th-2, including TNF-α, IL-10, and IL-2. Pfizer consistently broadens its market penetration and secures fresh authorizations for Eucrisa (crisaborole). For example, the FDA authorized Eucrisa in March 2020 for use in children older than three, expanding the medication's potential to generate income. Rofluminast, a PDE4 that is currently under development, is made by Arcutis Biotherapeutics. The business declared in January 2021 that the medication will begin a phase 3 study.
Thus, Because of their innovative approach, biologics are the fastest-growing sector in the market for drugs for atopic dermatitis. With their precise targeting and enhanced potency, monoclonal antibodies and other biologics particularly target the immunological mechanisms that underlie atopic dermatitis. In extreme conditions when standard therapies might not be sufficient, biologics have altered care with significant research investments and positive clinical outcomes. The industry's dedication to developing therapeutic alternatives beyond traditional therapies is seen in the increasing adoption of biologics. Biologics are the foundation of creative and successful atopic dermatitis treatments because of their capacity to modify the immune system, which has a long-lasting and focused effect and propels their explosive rise in the market.
Atopic Dermatitis Therapeutics Market Share (%) by Drug Class in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Atopic Dermatitis Therapeutics Industry. Request a Free Sample PDF!
End Users Segment Analysis
Based on End Users the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The high prevalence of atopic dermatitis, rising drug costs, and rising incomes of middle-class and lower-class families are all contributing factors to the hospital segment's dominance in the market in 2022 and are expected to continue so throughout the forecast period. Government funding for hospitals to upgrade their infrastructure is also anticipated to fuel the segment's growth.
The Hospitals segment dominates the atopic dermatitis market primarily due to several key factors as hospitals often serve as primary centers for diagnosing and treating severe cases of atopic dermatitis, particularly those requiring specialized care or advanced therapies. These institutions typically have access to a wide range of medical specialists, including dermatologists, allergists, and immunologists, who collaborate to develop comprehensive treatment plans for patients with atopic dermatitis. hospitals typically have better infrastructure and resources compared to other healthcare settings, allowing for the provision of a wide array of treatment options, including topical medications, phototherapy, systemic medications, and even advanced therapies like biologics. This comprehensive approach to treatment is essential for managing the complex and multifaceted nature of atopic dermatitis effectively.
Additionally, hospitals often serve as research and teaching centers, where clinicians are actively involved in clinical trials and research studies aimed at developing new therapies and advancing our understanding of the disease. This involvement in research and innovation enables hospitals to stay at the forefront of atopic dermatitis management and offer patients access to cutting-edge treatments and therapies. Hospitals frequently serve as referral centers for patients with severe or refractory atopic dermatitis, drawing in individuals from surrounding regions seeking specialized care. This patient influx contributes to the dominance of hospitals in the atopic dermatitis market, as they become central hubs for the diagnosis, treatment, and management of the condition.
Overall, the dominance of the hospital segment in the atopic dermatitis market can be attributed to its ability to provide comprehensive care, access to advanced treatments, involvement in research and innovation, and its role as a referral center for complex cases.
Atopic Dermatitis Therapeutics Market Share (%) by End User in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Atopic Dermatitis Therapeutics Route of Administration Segment Analysis
Route of Administration Segment Analysis
Based on the Route of Administration the market is segmented into Topical, Injectable, and Oral routes. Because injectable drugs like dupulimab are being used more often, the injectable category is expected to remain dominant in 2022 and beyond. The injectable biologics tofacitinib and ruxolitinib are undergoing clinical trials. Shortly, biologics are anticipated to alter the therapy landscape for Atopic Dermatitis. To address the significant unmet needs in this sector, they are being researched for the treatment of pediatric patients. For pediatric Atopic Dermatitis patients, therapy choices are quite restricted. The dupilumab development program is one of the clinical initiatives focused on creating Atopic Dermatitis medications for juvenile patients. Enhancing clinical research is the program's goal. Injectable usage for atopic dermatitis will also rise due to other medications. Atopic dermatitis' absence of therapy also made it more likely for participants to enter clinical trials and research and development, which will grow the injectable market.
With new introductions of JAK inhibitors, which are mainly taken orally, the oral category is expected to increase at the second-highest pace of 8.4% CAGR over the course of the projected year. When a disease has spread to significant portions of the body or when alternative medicines are not working as intended, oral corticosteroids are only administered in severe situations. Methotrexate, azathioprine, cyclosporine, and mycophenolate mofetil are the conventional oral drugs.
However, the injectable segment is expected to increase at a good pace over the period due to an increase in the use of injectable medications.
- Topical
- Injectable
- Oral
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
With the help of the above study about the Atopic Dermatitis Market, it can be concluded that the market for Atopic Dermatitis worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.
Frequently Asked Questions
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Atopic Dermatitis Therapeutics Market
In February 2023, the supplemental New Drug Application (sNDA) for CIBINQO (abrocitinib) was approved by the FDA, expanding the drug's indication to include adolescents (12 to 18 years old) with refractory, moderate-to-severe atopic dermatitis.
Source:(https://www.pharmaceutical-technology.com/news/pfizers-cibinqo-atopic-dermatitis/)
In February 2023, The ADORING 1 and 2 Phase 3 clinical trials using VTAMA (taping of) cream, 1% for the topical treatment of atopic dermatitis Atopic Dermatitis in adults and children as young as two years old have concluded patient recruitment, according to Dermavant Sciences.
Source:(https://dermavant.com/dermavant-presents-new-data-on-treatment-of-patients-with-skin-of-color-from-adoring-1-and-adoring-2/)
In January 2023, The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) approved Dupixent (dupilumab), and Sanofi has announced that this medication is now recommended for wider EU authorization to treat severe atopic dermatitis in children aged six months to five years who are candidates for systemic therapy.
Source:(https://www.sanofi.com/en/media-room/press-releases/2023/2023-01-27-06-00-00-2596599#:~:text=The%20European%20Medicines%20Agency's%20Committee,are%20candidates%20for%20systemic%20therapy.)
In January 2023, Sun Pharma, the leading pharmaceutical company in India based on market share, increased its presence in the US dermatological market by purchasing Concert Pharmaceuticals, Inc. (Concert) for $576 million.
Source:(https://www.reuters.com/markets/deals/indias-sun-pharma-acquire-us-based-concert-576-mln-2023-01-19/#:~:text=Jan%2019%20(Reuters)%20%2D%20Sun,drug%20for%20treating%20patchy%20baldness)
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Atopic Dermatitis Therapeutics Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Drug Class | Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others |
| End User | Hospitals, Research Lab, Clinics |
| Route of Administration | Topical, Injectable, Oral |
| List of Competitors | Abbvie Inc, Bayer AG, Allergan PLC, Novartis AG, Astellas Pharma Inc., GALDERMA LABORATORIES, L.P., F. Hoffmann-La Roche Ltd., Bausch Health Companies Inc, Nestle SA, Pfizer Inc, AstraZeneca, Regenron Pharmaceutical Inc, Evelo Biosciences, Cara Therapeutics, Bristol-Myers Squibb Company, GlaxoSmithKline PLC |
This chapter will help you gain GLOBAL Market Analysis of Atopic Dermatitis Therapeutics. Further deep in this chapter, you will be able to review Global Atopic Dermatitis Therapeutics Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Atopic Dermatitis Therapeutics Revenue Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Atopic Dermatitis Therapeutics Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Atopic Dermatitis Therapeutics Revenue Market Size By Region
-
-
1.3 Global Atopic Dermatitis Therapeutics Market Size By Drug Class 2019 -2031
-
1.3.1 Corticosteroids Market Size
-
1.3.2 Calcineurin Inhibitors Market Size
-
1.3.3 PDE4 Inhibitors Market Size
-
1.3.4 Biologics Market Size
-
1.3.5 Others Market Size
-
-
1.4 Global Atopic Dermatitis Therapeutics Market Size By End User 2019 -2031
-
1.4.1 Hospitals Market Size
-
1.4.2 Research Lab Market Size
-
1.4.3 Clinics Market Size
-
-
1.5 Global Atopic Dermatitis Therapeutics Market Size By Route of Administration 2019 -2031
-
1.5.1 Topical Market Size
-
1.5.2 Injectable Market Size
-
1.5.3 Oral Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Drug Class
-
1.7.3 Global Market Revenue Split By End User
-
1.7.4 Global Market Revenue Split By Route of Administration
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
This chapter will help you gain North America Market Analysis of Atopic Dermatitis Therapeutics. Further deep in this chapter, you will be able to review North America Atopic Dermatitis Therapeutics Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
-
2.1 North America Atopic Dermatitis Therapeutics Market Size 2019 - 2031
-
2.1.1 North America Atopic Dermatitis Therapeutics Market Size By Country 2019 - 2031
-
2.1.2 North America Atopic Dermatitis Therapeutics Market Size by Drug Class 2019 -2031
-
2.1.2.1 North America Corticosteroids Market Size
-
2.1.2.2 North America Calcineurin Inhibitors Market Size
-
2.1.2.3 North America PDE4 Inhibitors Market Size
-
2.1.2.4 North America Biologics Market Size
-
2.1.2.5 North America Others Market Size
-
-
2.1.3 North America Atopic Dermatitis Therapeutics Market Size by End User 2019 -2031
-
2.1.3.1 North America Hospitals Market Size
-
2.1.3.2 North America Research Lab Market Size
-
2.1.3.3 North America Clinics Market Size
-
-
2.1.4 North America Atopic Dermatitis Therapeutics Market Size by Route of Administration 2019 -2031
-
2.1.4.1 North America Topical Market Size
-
2.1.4.2 North America Injectable Market Size
-
2.1.4.3 North America Oral Market Size
-
-
This chapter will help you gain Europe Market Analysis of Atopic Dermatitis Therapeutics. Further deep in this chapter, you will be able to review Europe Atopic Dermatitis Therapeutics Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
-
3.1 Europe Atopic Dermatitis Therapeutics Market Size 2019 - 2031
-
3.1.1 Europe Atopic Dermatitis Therapeutics Market Size By Country 2019 - 2031
-
3.1.2 Europe Atopic Dermatitis Therapeutics Market Size by Drug Class 2019 -2031
-
3.1.2.1 Europe Corticosteroids Market Size
-
3.1.2.2 Europe Calcineurin Inhibitors Market Size
-
3.1.2.3 Europe PDE4 Inhibitors Market Size
-
3.1.2.4 Europe Biologics Market Size
-
3.1.2.5 Europe Others Market Size
-
-
3.1.3 Europe Atopic Dermatitis Therapeutics Market Size by End User 2019 -2031
-
3.1.3.1 Europe Hospitals Market Size
-
3.1.3.2 Europe Research Lab Market Size
-
3.1.3.3 Europe Clinics Market Size
-
-
3.1.4 Europe Atopic Dermatitis Therapeutics Market Size by Route of Administration 2019 -2031
-
3.1.4.1 Europe Topical Market Size
-
3.1.4.2 Europe Injectable Market Size
-
3.1.4.3 Europe Oral Market Size
-
-
This chapter will help you gain Asia Pacific Market Analysis of Atopic Dermatitis Therapeutics. Further deep in this chapter, you will be able to review Asia Pacific Atopic Dermatitis Therapeutics Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Atopic Dermatitis Therapeutics Market Size 2019 - 2031
-
4.1.1 Asia Pacific Atopic Dermatitis Therapeutics Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Atopic Dermatitis Therapeutics Market Size by Drug Class 2019 -2031
-
4.1.2.1 Asia Pacific Corticosteroids Market Size
-
4.1.2.2 Asia Pacific Calcineurin Inhibitors Market Size
-
4.1.2.3 Asia Pacific PDE4 Inhibitors Market Size
-
4.1.2.4 Asia Pacific Biologics Market Size
-
4.1.2.5 Asia Pacific Others Market Size
-
-
4.1.3 Asia Pacific Atopic Dermatitis Therapeutics Market Size by End User 2019 -2031
-
4.1.3.1 Asia Pacific Hospitals Market Size
-
4.1.3.2 Asia Pacific Research Lab Market Size
-
4.1.3.3 Asia Pacific Clinics Market Size
-
-
4.1.4 Asia Pacific Atopic Dermatitis Therapeutics Market Size by Route of Administration 2019 -2031
-
4.1.4.1 Asia Pacific Topical Market Size
-
4.1.4.2 Asia Pacific Injectable Market Size
-
4.1.4.3 Asia Pacific Oral Market Size
-
-
This chapter will help you gain South America Market Analysis of Atopic Dermatitis Therapeutics. Further deep in this chapter, you will be able to review South America Atopic Dermatitis Therapeutics Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
-
5.1 South America Atopic Dermatitis Therapeutics Market Size 2019 - 2031
-
5.1.1 South America Atopic Dermatitis Therapeutics Market Size By Country 2019 - 2031
-
5.1.2 South America Atopic Dermatitis Therapeutics Market Size by Drug Class 2019 -2031
-
5.1.2.1 South America Corticosteroids Market Size
-
5.1.2.2 South America Calcineurin Inhibitors Market Size
-
5.1.2.3 South America PDE4 Inhibitors Market Size
-
5.1.2.4 South America Biologics Market Size
-
5.1.2.5 South America Others Market Size
-
-
5.1.3 South America Atopic Dermatitis Therapeutics Market Size by End User 2019 -2031
-
5.1.3.1 South America Hospitals Market Size
-
5.1.3.2 South America Research Lab Market Size
-
5.1.3.3 South America Clinics Market Size
-
-
5.1.4 South America Atopic Dermatitis Therapeutics Market Size by Route of Administration 2019 -2031
-
5.1.4.1 South America Topical Market Size
-
5.1.4.2 South America Injectable Market Size
-
5.1.4.3 South America Oral Market Size
-
-
This chapter will help you gain Middle East and Africa Market Analysis of Atopic Dermatitis Therapeutics. Further deep in this chapter, you will be able to review Middle East and Africa Atopic Dermatitis Therapeutics Market Split by various segments and Country Split.
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Atopic Dermatitis Therapeutics Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Atopic Dermatitis Therapeutics Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Atopic Dermatitis Therapeutics Market Size by Drug Class 2019 -2031
-
6.1.2.1 Middle East and Africa Corticosteroids Market Size
-
6.1.2.2 Middle East and Africa Calcineurin Inhibitors Market Size
-
6.1.2.3 Middle East and Africa PDE4 Inhibitors Market Size
-
6.1.2.4 Middle East and Africa Biologics Market Size
-
6.1.2.5 Middle East and Africa Others Market Size
-
-
6.1.3 Middle East and Africa Atopic Dermatitis Therapeutics Market Size by End User 2019 -2031
-
6.1.3.1 Middle East and Africa Hospitals Market Size
-
6.1.3.2 Middle East and Africa Research Lab Market Size
-
6.1.3.3 Middle East and Africa Clinics Market Size
-
-
6.1.4 Middle East and Africa Atopic Dermatitis Therapeutics Market Size by Route of Administration 2019 -2031
-
6.1.4.1 Middle East and Africa Topical Market Size
-
6.1.4.2 Middle East and Africa Injectable Market Size
-
6.1.4.3 Middle East and Africa Oral Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Atopic Dermatitis Therapeutics Market Size by Drug Class 2019 -2031
-
7.1.2 Country 1Atopic Dermatitis Therapeutics Market Size by End User 2019 -2031
-
7.1.3 Country 1Atopic Dermatitis Therapeutics Market Size by Route of Administration 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
This chapter provides an in-depth analysis of the market share among key competitors of Atopic Dermatitis Therapeutics. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Atopic Dermatitis Therapeutics Market Revenue and Share by Key Players
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Abbvie Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Bayer AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Allergan PLC
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Novartis AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Astellas Pharma Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 GALDERMA LABORATORIES
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 L.P.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 F. Hoffmann-La Roche Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Bausch Health Companies Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Nestle SA
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Pfizer Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 AstraZeneca
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 Regenron Pharmaceutical Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
8.2.14 Evelo Biosciences
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.14.2 Business Overview
-
8.2.14.3 Financials (Subject to data availability)
-
8.2.14.4 Product Types Specification
-
8.2.14.5 Business Strategy
-
8.2.14.6 S.W.O.TAnalysis
-
-
8.2.15 Cara Therapeutics
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.15.2 Business Overview
-
8.2.15.3 Financials (Subject to data availability)
-
8.2.15.4 Product Types Specification
-
8.2.15.5 Business Strategy
-
8.2.15.6 S.W.O.TAnalysis
-
-
8.2.16 Bristol-Myers Squibb Company
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.16.2 Business Overview
-
8.2.16.3 Financials (Subject to data availability)
-
8.2.16.4 Product Types Specification
-
8.2.16.5 Business Strategy
-
8.2.16.6 S.W.O.TAnalysis
-
-
8.2.17 GlaxoSmithKline PLC
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.17.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.17.2 Business Overview
-
8.2.17.3 Financials (Subject to data availability)
-
8.2.17.4 Product Types Specification
-
8.2.17.5 Business Strategy
-
8.2.17.6 S.W.O.TAnalysis
-
-
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Restraints
-
9.3 Market Trends
-
9.4 Market Opportunity
-
9.5 Technological Road Map (Subject to Data Availability)
-
9.6 Product Life Cycle (Subject to Data Availability)
-
9.7 Consumer Preference Analysis
-
9.8 Market Attractiveness Analysis
-
9.9 PESTEL Analysis
-
9.9.1 Political Factors
-
9.9.2 Economic Factors
-
9.9.3 Social Factors
-
9.9.4 Technological Factors
-
9.9.5 Legal Factors
-
9.9.6 Environmental Factors
-
-
9.10 Industrial Chain Analysis (Subject to Data Availability)
-
9.10.1 Industry Chain Analysis
-
9.10.2 Manufacturing Cost Analysis
-
9.10.3 Supply Side Analysis
-
9.10.3.1 Raw Material Analysis
-
9.10.3.2 Raw Material Procurement Analysis
-
9.10.3.3 Raw Material Price Trend Analysis
-
-
-
9.11 Porter’s Five Forces Analysis
-
9.11.1 Bargaining Power of Suppliers
-
9.11.2 Bargaining Power of Buyers
-
9.11.3 Threat of New Entrants
-
9.11.4 Threat of Substitutes
-
9.11.5 Degree of Competition
-
-
9.12 Patent Analysis (Subject to Data Availability)
-
9.13 ESG Analysis
Segmentation Drug Class Analysis 2019 -2031, will provide market size split by Drug Class . This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Drug Class Analysis 2019 -2031
-
10.1 Corticosteroids
-
10.1.1 Global Atopic Dermatitis Therapeutics Revenue Market Size and Share by Corticosteroids 2019 -2031
-
-
10.2 Calcineurin Inhibitors
-
10.2.1 Global Atopic Dermatitis Therapeutics Revenue Market Size and Share by Calcineurin Inhibitors 2019 -2031
-
-
10.3 PDE4 Inhibitors
-
10.3.1 Global Atopic Dermatitis Therapeutics Revenue Market Size and Share by PDE4 Inhibitors 2019 -2031
-
-
10.4 Biologics
-
10.4.1 Global Atopic Dermatitis Therapeutics Revenue Market Size and Share by Biologics 2019 -2031
-
-
10.5 Others
-
10.5.1 Global Atopic Dermatitis Therapeutics Revenue Market Size and Share by Others 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by End User Analysis 2019 -2031
-
11.1 Hospitals
-
11.1.1 Global Atopic Dermatitis Therapeutics Revenue Market Size and Share by Hospitals 2019 - 2031
-
-
11.2 Research Lab
-
11.2.1 Global Atopic Dermatitis Therapeutics Revenue Market Size and Share by Research Lab 2019 - 2031
-
-
11.3 Clinics
-
11.3.1 Global Atopic Dermatitis Therapeutics Revenue Market Size and Share by Clinics 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Route of Administration Analysis 2019 -2031
-
12.1 Topical
-
12.1.1 Global Atopic Dermatitis Therapeutics Revenue Market Size and Share by Topical 2019 -2031
-
-
12.2 Injectable
-
12.2.1 Global Atopic Dermatitis Therapeutics Revenue Market Size and Share by Injectable 2019 -2031
-
-
12.3 Oral
-
12.3.1 Global Atopic Dermatitis Therapeutics Revenue Market Size and Share by Oral 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Atopic Dermatitis Therapeutics market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Atopic Dermatitis Therapeutics Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Atopic Dermatitis Therapeutics Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Atopic Dermatitis Therapeutics Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Atopic Dermatitis Therapeutics Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Atopic Dermatitis Therapeutics Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Atopic Dermatitis Therapeutics Market
Key Questions Answered By Atopic Dermatitis Therapeutics Market Report 2024
| Why Corticosteroids have a significant impact on Atopic Dermatitis Therapeutics market? |
| What are the key factors affecting the Corticosteroids and Calcineurin Inhibitors of Atopic Dermatitis Therapeutics Market? |
| What is the CAGR/Growth Rate of Hospitals during the forecast period? |
| By type, which segment accounted for largest share of the global Atopic Dermatitis Therapeutics Market? |
| Which region is expected to dominate the global Atopic Dermatitis Therapeutics Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
